|1.||Maioli, Emanuela: 5 articles (01/2015 - 06/2009)|
|2.||Valacchi, Giuseppe: 5 articles (01/2015 - 06/2009)|
|3.||Kwon, Taeg Kyu: 5 articles (04/2012 - 11/2008)|
|4.||Shankar, Sharmila: 4 articles (10/2014 - 11/2012)|
|5.||Srivastava, Rakesh K: 4 articles (10/2014 - 11/2012)|
|6.||Lim, Jun Hee: 4 articles (04/2012 - 11/2008)|
|7.||Torricelli, C: 3 articles (04/2015 - 03/2008)|
|8.||Valacchi, G: 3 articles (04/2015 - 03/2008)|
|9.||Maioli, E: 3 articles (04/2015 - 03/2008)|
|10.||Kumar, Dhruv: 3 articles (02/2014 - 11/2012)|
09/01/2008 - "The present study was designed to investigate the modulatory effects of rottlerin on ischemia reperfusion induced myocardial injury. "
09/01/2008 - "Rottlerin, a selective PKCdelta inhibitor, did not modulate ischemia-reperfusion (I/R) induced myocardial injury at low dose (3 microM). "
01/01/2002 - "Therefore, we utilized the PKC-delta selective antagonist, rottlerin, to assess the effect of inhibition of this isozyme on cardioprotection induced by one-cycle of IPC prior to 30 minutes of ischemia and 2 hours of reperfusion. "
04/01/2005 - "The PKC inhibitors chelerythrine (1 or 5 mg/kg) or rottlerin (selective for PKC-delta isoform; 0.3 mg/kg) were administered intravenously as a single bolus 15 min before ischemia. "
09/01/2007 - "DADLE reduced infarct size after 35 min of ischemia followed by 2 h of reperfusion by 69%, and PKC-epsilon-TIP and rottlerin eliminated 48% and 63%, respectively, of the infarct size-limiting effect of DADLE. "
12/01/2006 - "Because our initial studies of this agent in a series of glioma cell lines showed only partial growth inhibition at clinically achievable concentrations, we questioned whether inhibition of PKC signaling using the PKC-delta inhibitor rottlerin might potentiate therapeutic efficacy. "
01/27/2005 - "Since rottlerin can sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells but not human astrocytes to TRAIL-induced apoptosis, this combined treatment may offer an attractive strategy for safely treating resistant gliomas."
01/27/2005 - "Taken together, inhibition of Cdc2 activity and the subsequent downregulation of survivin and XIAP by subtoxic doses of rottlerin contribute to amplification of caspase cascades, thereby overcoming resistance of glioma cells to TRAIL-mediated apoptosis. "
01/27/2005 - "Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP."
12/01/2006 - "Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells."
12/01/2007 - "Additionally, compared with vehicle, the ratio of the wet lung weights to dry lung weights was significantly greater on exposure of animals to rottlerin; rottlerin also produced a dose-dependent increase in EBD extravasation into the lungs. "
12/01/2007 - "Taken together, rottlerin increases barrier dysfunction in pulmonary endothelial cell monolayers and causes pulmonary edema in rats; results suggestive of an important role for PKCdelta in maintaining lung endothelial barrier function."
12/01/2007 - "To determine whether the effects noted in vitro correlated with changes in intact lungs, we tested the effects of rottlerin in the formation of pulmonary edema in rats using both ex vivo and in vivo models. "
12/01/2007 - "Rottlerin causes pulmonary edema in vivo: a possible role for PKCdelta."
04/15/2012 - "Collectively, the results of this study demonstrate, for the first time, that upregulation of NAG-1 contributes to rottlerin-induced apoptosis in cancer cells."
10/10/2014 - "Rottlerin-treated mice showed a significant inhibition in tumor growth which was associated with suppression of cell proliferation, activation of capase-3 and cleavage of PARP. "
10/10/2014 - "AsPC-1 cells were injected subcutaneously into Balb c nude mice, and tumor-bearing mice were treated with rottlerin. "
01/01/2014 - "Rottlerin (ROT), a polyphenolic compound initially identified as a PKC-δ inhibitor, induces apoptosis and autophagy in a variety of cancer cells including PaCa cells. "
09/27/2013 - "Rottlerin (1), along with rottlerone (2c) and mallotus B (2d), was evaluated for cytotoxicity against a panel of cancer cell lines including HEPG2, Colo205, MIAPaCa-2, PC-3, and HL-60 cells. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
10/10/2014 - "Taken together, our data show that the rottlerin induces apoptosis and inhibits pancreatic cancer growth by targeting Akt, Notch and Shh signaling pathways, and provide a new therapeutic approach with translational potential for humans. "
10/10/2014 - "These data suggest that rottlerin can inhibit pancreatic cancer growth by suppressing multiple signaling pathways which are constitutively active in pancreatic cancer. "
10/10/2014 - "The effects of rottlerin on pancreatic cancer cells isolated from Kras(G12D) mice were also examined. "
11/01/2012 - "Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells."
01/01/2010 - "Thus rottlerin represents a promising novel agent for pancreatic cancer treatment."
|1.||Protein Kinase C-epsilon
|2.||Leucine-2-Alanine Enkephalin (Enkephalin, Leucine 2 Alanine)
|3.||Protein Kinase C
|5.||2- (1- (3- dimethylaminopropyl)- 5- methoxyindol- 3- yl)- 3- (1H- indol- 3- yl)maleimide
|6.||Collagen Type I (Type I Collagen)
|8.||Immunoglobulin E (IgE)
|9.||Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone (FCCP)
|1.||Heterologous Transplantation (Xenotransplantation)